PrecigenPGEN
Market Cap: $293M
About: Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Employees: 202
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
773% more call options, than puts
Call options by funds: $777K | Put options by funds: $89K
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
6% more capital invested
Capital invested by funds: $90.9M [Q1] → $96M (+$5.09M) [Q2]
2% more funds holding
Funds holding: 129 [Q1] → 131 (+2) [Q2]
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
1.12% less ownership
Funds ownership: 25.19% [Q1] → 24.07% (-1.12%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JMP Securities Jason Butler 49% 1-year accuracy 20 / 41 met price target | 600%upside $7 | Market Outperform Maintained | 15 Aug 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 34% 1-year accuracy 47 / 139 met price target | 300%upside $4 | Buy Maintained | 15 Aug 2024 |